Published in Oncology Business Week, March 4th, 2007
This is the second pharmacogenetic test of its kind launched by PGxHealth in recent months. The assay is based on a worldwide exclusive license to an intellectual property portfolio from Innate Pharma S.A. of Marseille, France.
PGxPredict:Rituximab is a pharmacogenetic test that helps physicians predict the likelihood of a given patient responding to rituximab monotherapy in...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Oncology Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.